What is Zacks Research's Forecast for Masimo Q1 Earnings?

Masimo Co. (NASDAQ:MASI - Free Report) - Equities researchers at Zacks Research cut their Q1 2027 earnings estimates for Masimo in a report released on Tuesday, May 27th. Zacks Research analyst I. Bandyopadhyay now expects that the medical equipment provider will earn $1.39 per share for the quarter, down from their previous forecast of $1.59. The consensus estimate for Masimo's current full-year earnings is $4.10 per share.

Several other equities analysts also recently commented on the stock. Raymond James lowered their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Wall Street Zen downgraded shares of Masimo from a "buy" rating to a "hold" rating in a research note on Friday. Wells Fargo & Company lowered their price objective on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Finally, BTIG Research set a $193.00 price objective on shares of Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $191.60.

Masimo Trading Up 2.8%

Shares of NASDAQ:MASI traded up $4.39 during midday trading on Thursday, hitting $161.36. 1,085,666 shares of the stock traded hands, compared to its average volume of 651,832. The stock has a market capitalization of $8.75 billion, a PE ratio of 111.28 and a beta of 1.23. The business's 50 day moving average is $157.13 and its two-hundred day moving average is $167.15. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo has a one year low of $101.61 and a one year high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.12. The business had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company's revenue was down 24.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.77 earnings per share.

Institutional Investors Weigh In On Masimo

A number of hedge funds and other institutional investors have recently bought and sold shares of MASI. FMR LLC grew its holdings in Masimo by 19.8% in the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock worth $1,338,509,000 after purchasing an additional 1,340,836 shares during the period. Durable Capital Partners LP purchased a new stake in Masimo in the first quarter worth about $187,528,000. Capital Research Global Investors grew its holdings in Masimo by 80.5% in the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock worth $405,807,000 after purchasing an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Masimo by 119.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after purchasing an additional 943,001 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in Masimo by 1,276.9% in the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock worth $156,604,000 after purchasing an additional 878,587 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Insider Buying and Selling

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Bilal Muhsin sold 10,000 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at approximately $3,946,804.16. This trade represents a 29.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,053 shares of company stock valued at $6,998,565 over the last three months. Corporate insiders own 9.70% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.